<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112681">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978366</url>
  </required_header>
  <id_info>
    <org_study_id>HALO-DMD-02</org_study_id>
    <secondary_id>HALO   [Halo Therapeutics]</secondary_id>
    <nct_id>NCT01978366</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of HT-100 in Patients With DMD</brief_title>
  <official_title>An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Halo Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Halo Therapeutics, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide 6-months continuous dosing with the study medication,
      called HT-100, on participants who successfully completed the predecessor study
      (HALO-DMD-01). The main purpose of this study is to assess chronic safety, tolerability,
      pharmacodynamic activity (testing the drug's effect on DMD) and population pharmacokinetics
      (measuring how much drug is in the bloodstream) in participants with a broad spectrum of
      Duchenne muscular dystrophy (DMD).
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    FDA placed the protocol on clinical hold while new data are evaluated. Enrolled subjects are
    not taking HT-100. Clinic visits are continuing per protocol.
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of administration of 6 months of chronic, oral, multiple doses of HT-100 to boys with DMD.</measure>
    <time_frame>Months 2, 4, 6, 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Target Safety profile by review of adverse events (AEs)
Physical examination findings
Clinical laboratory test results
Other diagnostic testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic signals of HT-100 following chronic oral administration of multiple doses to boys with DMD.</measure>
    <time_frame>Months 4, 6, 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pulmonary function
Motor function
Muscle composition
Biochemical and imaging markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic plasma profile of HT-100 following chronic oral administration of multiple doses to boys with DMD.</measure>
    <time_frame>Months 4, 6</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Halofuginone plasma concentrations</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: HT-100 tablet, Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•     Multiple dose administration: Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: HT-100 tablet, Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•     Multiple dose administration: Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: HT-100 tablet, Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•     Multiple dose administration: Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: HT-100 tablet, Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•     Multiple dose administration: Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: HT-100 tablet, Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•     Multiple dose administration: Dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HT-100</intervention_name>
    <arm_group_label>Cohort 1: HT-100 tablet, Dose 1</arm_group_label>
    <arm_group_label>Cohort 2: HT-100 tablet, Dose 2</arm_group_label>
    <arm_group_label>Cohort 3: HT-100 tablet, Dose 3</arm_group_label>
    <arm_group_label>Cohort 4: HT-100 tablet, Dose 4</arm_group_label>
    <arm_group_label>Cohort 5: HT-100 tablet, Dose 5</arm_group_label>
    <other_name>halofuginone hydrobromide delayed-release tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed both the single ascending dose (SAD) and multiple ascending dose (MAD)
             phases of predecessor study HALO-DMD-01

          -  Maintained the same corticosteroid therapy  from the predecessor study HALO-DMD-01

          -  Ability to provide written informed consent

          -  Ambulatory or non-ambulatory

        Exclusion Criteria:

          -  Recent, substantial change in use of cardiac medications or medications affecting
             muscle function

          -  Clinically significant major disease, not related to DMD

          -  Significantly compromised cardio-respiratory function

          -  History of severe allergic or anaphylactic reactions

          -  Prior treatment with another investigational product in past 6 months

          -  Inability to undergo magnetic resonance imaging (MRI)

          -  Current drug or alcohol abuse or prior treatment for abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana M Escolar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Halo Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute, Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.halotherapeutics.com/</url>
    <description>Sponsor company website</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>halofuginone hydrobromide</keyword>
  <keyword>anti-fibrotic</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>muscle regeneration</keyword>
  <keyword>protein synthesis inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protein Synthesis Inhibitors</mesh_term>
    <mesh_term>Halofuginone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
